Generic vs Name Brand Drugs

Slides:



Advertisements
Similar presentations
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Advertisements

FDA Counsel.com 1 ANDAs, OTCs, Orphans and Cosmetics -- Key Issues Wednesday, August 18, 2004 SDRAN RAC STUDY COURSE Michael A. Swit, Esq. FDACounsel.com.
Joan Bergstrom Henkel Consumer Goods, Inc.
The Hatch-Waxman Act and How it Works: Balancing Incentives to Innovate with the Need for Affordable Drugs Minnesota Intellectual Property Association.
Going Beyond the Current Regulatory and Incentives Frameworks A new proposal to foster greater orphan drug development 1.
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
RAC Study Group Chapter 16
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
The Korus FTA Will Lead to Higher Drug Prices in Korea
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
© 2009 Pharmaceutical Law Group PC Market Exclusivity Paradigm Gregory J. Glover, MD, JD Pharmaceutical Law Group
Generic Substitution Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Authorized Generics: Good For Everyone (Even Generics) Jerome A. Swindell Senior Counsel.
Selection Sourcing Structure Standardization Safety Substantiation
The Regulatory Authority for Off-Label Promotion
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
1 Non-Sedating Antihistamines Rx-to-OTC Switch NDAC & PADAC Joint Meeting May 11, 2001 François Nader, MD Senior Vice-President Medical & Regulatory Affairs,
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
© 2008 Dechert LLP Pharma v. Pharma or Pharma & Pharma: The Legal Interface Between the Makers of Original and Copied Versions of Medicines AIPLA Antitrust,
Medications Chapter 5. Statistics  2009 Most Prescribed  Vicodin  Zokor  Zestril  Levoxyl  Zithromax  Illicit Drugs  Prescription Drugs  Projected.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Biotechnology Chemical Pharmaceutical Customer Partnership
Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
Initiatives Drive Pediatric Drug Development January 30, 2002.
FDA GUIDELINES FOR ADVERTISING COPYWRITERS At the end of this module, you will be able to recall FDA regulations related to pharmaceutical advertising.
 An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
Regulation of Generic Animal Drugs in the United States
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Recent FTC Pharmaceutical Cases: Background and Examples Sue H. Kim This presentation was prepared from public sources. The views expressed herein do not.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
iHEA 9th World Congress Sydney, July 8, 2013
Difference to Generics What can they do for us in the future
New Drug Application(NDA) Vs Abbreviated new drug application (ANDA)
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
Efficacy and Safety of Medicines
Who pays for today’s healthcare?
Henry Schein Rx Samples
BASICS IN PHARMA.
The Top apps in pediatrics for your calls and shifts Dr
Clinical Trials — A Closer Look
Interactive Session: Presentation of Scenarios and Q&A
“New Gene Therapy Treatments Will Carry Whopping Price Tags”
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Clinical Trials Medical Interventions
Medications.
Generic Medicines.
Using Medicines Safely (2:50)
Hatch-Waxman Overview
Biotechnology Chemical Pharmaceutical Customer Partnership
CHAWLA MEDICOS Present’s Branded v/s Generic medicine
9.4 Product Quality Control
Prescription for Pharmaceutical Reform: Healing an Ailing System
A Non-profit patient advocacy agency
Clinical Trials.
Pharma Workshop IV Patent Linkage in the USA
Using Medicines Safely (2:50)
Monopoly.
Pharmaceutical Industry & Consumers
Pediatric Therapeutics Still working to get it right for kids
Compounded Drugs and Lack of Premarket FDA-Approval
Pharmaceuticals Industry
Presentation transcript:

Generic vs Name Brand Drugs Scientistmel.com Twitter.com/scientistmel Patreon.com/scientistmel 4/13/2019 10 am

Drugs What are they? Compare/Contrast? How does it all work? What about cost?

Generic vs Brand Breakdown Same active ingredients, efficacy, entry (oral, IV) Same mode of molecular interaction Vary in inactive ingredients, packaging, and cost Drug development/Research is main difference

NP 1. First thing we have to do to explain the difference between the two is how a drug comes to market. The fda is a great resource on the differences between the two and how drugs come to market.  Space.com is a great resource to find an easy breakdown of the current working theories for the multiverse.

Discovery/Development Brand Drugs Discovery/Development Preclinical Research Clinical Research FDA Review FDA Monitoring There are 5 working theories regarding a multiverse.

Drugs

NP It can cost as much as $802 million over a period of 10-15 years to get a drug to market. Once the drug is approved, a patent is given to the company to allow it to recoup costs as well as make a profit. A patent lasts for 20 years. There are patents and there is exclusivity. FDA website states the difference: Patents and exclusivity work in a similar fashion but are distinct from one another and governed by different statutes. Patents are a property right granted by the United States Patent and Trademark Office anytime during the development of a drug and can encompass a wide range of claims.  Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.  A new drug application (NDA) or abbreviated new drug application (ANDA) holder is eligible for exclusivity if statutory requirements are met.  See 21 C.F.R. 314.108, 316.31, 316.34 and sections 505A, 505E, and 505(j)(5)(B)(iv) of the FD&C Act.  Periods of exclusivity and patent terms may or may not run concurrently. Exclusivity was designed to promote a balance between new drug innovation and greater public access to drugs that result from generic drug competition  

NP Orphan Drug Exclusivity (ODE) – 7 years New Chemical Entity Exclusivity (NCE) – 5 years Generating Antibiotic Incentives Now (GAIN) Exclusivity– 5 years added to certain exclusivities New Clinical Investigation Exclusivity – 3 years Pediatric Exclusivity (PED) – 6 months added to existing Patents/Exclusivity Patent Challenge (PC) – 180 days (this exclusivity is for ANDAs only) Competitive Generic Therapy (CGT) - 180 days (this exclusivity is for ANDAs only  

Generic Drugs Pharmaceutically equal Correct manufacture Consistent manufacture Same active ingredients Same amount of active ingredients Inactive ingredients are safe Drug does not break down over time Appropriate packaging Same label Relevant patents/exclusivities expired Let’s like at this info graphic from the FDA on drug approval.

NP What if the generic med acts differently in me than the name brand? Some studies in past research have shown that there can be approximately 4% difference between brand name drugs and generic…according to Dr. Choudhry at Harvard University. The FDA allows as much as 20% variance, but only about 4% is seen in the market. It is important to note that the FDA does not require human testing for generic drugs. They require proof that it is the same drug…not the same effects. However, given that the compound in itself has already undergone extensive testing, the added testing for generic medications is not considered necessary as any added health risk would not be likely at all. The idea is to get life saving medications on the market at a lower cost for those who can not afford name brands recouping the extensive cost of research.  

NP Nearly 8 out of 10 prescriptions in the US are filled as generic. Generic tend to be 80-85% less than name brands. Let’s take a look at a graphic from blue cross blue shield on the cost of generic vs name brand drugs…  

NP While there may be some differences between generic and name brand drugs, the differences don’t really outweigh the benefit of choosing generic over name brand….especially given the cost and the US does not have a national health care system. Generic meds can still be expensive to the point of financially crippling. It’s time to take a look at the current system as research is expensive yet necessary to limit human suffering. Perhaps we really do need an overhaul on healthcare ti ensure people have access to medications that increase quality of life.  

SOURCES https://www.scientificamerican.com/article/whats-the-difference-betw-2004-12-13/ https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs /ucm167991.htm https://www.fda.gov/drugs/developmentapprovalprocess/ucm079031.htm#howlongpatentterm https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs /ucm506040.htm https://www.health.harvard.edu/staying-healthy/do-generic-drugs-compromise-on-quality https://www.bcbsm.com/content/dam/public/Consumer/Documents/about-us/brand-name-vs- generic-drug-costs.pdf https://www.health.harvard.edu/drugs-and-medications/the-cost-of-generic-and-name-brand- drugs

Drugs What are they? Compare/Contrast? How does it all work? What about cost?

Generic vs Brand Breakdown Same active ingredients, efficacy, entry (oral, IV) Same mode of molecular interaction Vary in inactive ingredients, packaging, and cost Drug development/Research is main difference

You can find me… ScientistMel.com Patreon.com/scientistmel Pscp.tv.com/scientistmel Youtube.com/scientistmel Facebook.com/scientistmel New patrons…Mark Sykes, Derp State, Rhetoric and Discourse

NP New patrons…Mark Sykes, Derp State, Rhetoric and Discourse Talk about goals…and hopes for more patrons.  

Generic vs Name Brand Drugs Scientistmel.com Twitter.com/scientistmel Patreon.com/scientistmel 4/13/2019 10 am